Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 20/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 19/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12432542 | 0.87 | OPRD1 (0.72) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL12432534 | 0.87 | OPRD1 (0.71) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL474620 | 0.86 | OPRD1 (0.70) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL4922241 | 0.85 | OPRD1 (0.70) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL5780666 | 0.83 | OPRD1 (0.51) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL474192 | 0.81 | OPRM1 (0.64) | OPRD1OPRM1 | |
| SCHEMBL14228324 | 0.80 | OPRD1 (0.67) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL474252 | 0.80 | OPRM1 (0.62) | OPRD1OPRM1OPRK1KCNH2 | |
| Azd-7268 SCHEMBL30248100 | 0.79 | OPRD1 (1.00) | OPRD1OPRM1KCNH2 | |
| Azd-7268 SCHEMBL474151 | 0.79 | OPRD1 (1.00) | OPRD1OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079735-B1 | N- (2 -HYDROXYETHYL) -N-METHYL- 4- (QUINOLIN- 8-YL (1- (THIAZOL-4- YLMETHYL) PIPERIDIN- 4 -YLIDENE) METHYL) BENZAMIDE, THE PROCESS OF MAKING IT AS WELL AS ITS USE FOR THE TREATMENT OF PAIN, ANXIETY AND DEPRESSION. | ASTRAZENECA AB (SE) | 2012-02-01 | — | — | EP | claimed |
| JP-4668346-B2 | — | — | 2011-04-13 | — | — | JP | claimed |
| US-20100160374-A1 | N-(2-Hydroxyethyl)-N-Methyl-4-(Quinolin-8-yl(1-(Thiazol-4-ylmethyl)Piperidin-4-ylidene)Methyl)Benzamide | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | claimed |
| JP-2010506910-A | — | — | 2010-03-04 | — | — | JP | claimed |
| US-7659286-B2 | N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide | ASTRAZENECA AB (SE) | 2010-02-09 | — | — | US | claimed |
| EP-2079735-A1 | N- (2 -HYDROXYETHYL) -N-METHYL- 4- (QUINOLIN- 8-YL (1- (THIAZOL-4- YLMETHYL) PIPERIDIN- 4 -YLIDENE) METHYL) BENZAMIDE, THE PROCESS OF MAKING IT AS WELL AS ITS USE FOR THE TREATMENT OF PAIN, ANXIETY AND DEPRESSION. | AstraZeneca AB (SE) | 2009-07-22 | — | — | EP | claimed |
| US-20080182875-A1 | N-(2-Hydroxyethyl)-N-Methyl-4-(Quinolin-8-yl(1-(Thiazol-4-ylmethyl)Piperidin-4-ylidene)Methyl)Benzamide | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | US | claimed |
| WO-2008048171-A1 | N- (2 -HYDROXYETHYL) -N-METHYL- 4- (QUINOLIN- 8-YL (1- (THIAZOL-4- YLMETHYL) PIPERIDIN- 4 -YLIDENE) METHYL) BENZAMIDE, THE PROCESS OF MAKING IT AS WELL AS ITS USE FOR THE TREATMENT OF PAIN, ANXIETY AND DEPRESSION. | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | WO | claimed |
| EP-2079735-B1 | N- (2 -HYDROXYETHYL) -N-METHYL- 4- (QUINOLIN- 8-YL (1- (THIAZOL-4- YLMETHYL) PIPERIDIN- 4 -YLIDENE) METHYL) BENZAMIDE, THE PROCESS OF MAKING IT AS WELL AS ITS USE FOR THE TREATMENT OF PAIN, ANXIETY AND DEPRESSION. | ASTRAZENECA AB (SE) | 2012-02-01 | — | — | EP | disclosed |
| EP-2079735-B1 | N- (2 -HYDROXYETHYL) -N-METHYL- 4- (QUINOLIN- 8-YL (1- (THIAZOL-4- YLMETHYL) PIPERIDIN- 4 -YLIDENE) METHYL) BENZAMIDE, THE PROCESS OF MAKING IT AS WELL AS ITS USE FOR THE TREATMENT OF PAIN, ANXIETY AND DEPRESSION. | ASTRAZENECA AB (SE) | 2012-02-01 | — | — | EP | disclosed |
| US-7977355-B2 | N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl | ASTRAZENECA AB (SE) | 2011-07-12 | — | — | US | disclosed |
| US-7977355-B2 | N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl | ASTRAZENECA AB (SE) | 2011-07-12 | — | — | US | disclosed |
| US-7977355-B2 | N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl | ASTRAZENECA AB (SE) | 2011-07-12 | — | — | US | disclosed |
| US-20100160374-A1 | N-(2-Hydroxyethyl)-N-Methyl-4-(Quinolin-8-yl(1-(Thiazol-4-ylmethyl)Piperidin-4-ylidene)Methyl)Benzamide | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | disclosed |
| EP-2079735-A1 | N- (2 -HYDROXYETHYL) -N-METHYL- 4- (QUINOLIN- 8-YL (1- (THIAZOL-4- YLMETHYL) PIPERIDIN- 4 -YLIDENE) METHYL) BENZAMIDE, THE PROCESS OF MAKING IT AS WELL AS ITS USE FOR THE TREATMENT OF PAIN, ANXIETY AND DEPRESSION. | AstraZeneca AB (SE) | 2009-07-22 | — | — | EP | disclosed |
| US-20080182875-A1 | N-(2-Hydroxyethyl)-N-Methyl-4-(Quinolin-8-yl(1-(Thiazol-4-ylmethyl)Piperidin-4-ylidene)Methyl)Benzamide | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | US | disclosed |
| US-20080182875-A1 | N-(2-Hydroxyethyl)-N-Methyl-4-(Quinolin-8-yl(1-(Thiazol-4-ylmethyl)Piperidin-4-ylidene)Methyl)Benzamide | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | US | disclosed |
| US-20080182875-A1 | N-(2-Hydroxyethyl)-N-Methyl-4-(Quinolin-8-yl(1-(Thiazol-4-ylmethyl)Piperidin-4-ylidene)Methyl)Benzamide | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | US | disclosed |
| WO-2008048171-A1 | N- (2 -HYDROXYETHYL) -N-METHYL- 4- (QUINOLIN- 8-YL (1- (THIAZOL-4- YLMETHYL) PIPERIDIN- 4 -YLIDENE) METHYL) BENZAMIDE, THE PROCESS OF MAKING IT AS WELL AS ITS USE FOR THE TREATMENT OF PAIN, ANXIETY AND DEPRESSION. | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008048171-A1 | N- (2 -HYDROXYETHYL) -N-METHYL- 4- (QUINOLIN- 8-YL (1- (THIAZOL-4- YLMETHYL) PIPERIDIN- 4 -YLIDENE) METHYL) BENZAMIDE, THE PROCESS OF MAKING IT AS WELL AS ITS USE FOR THE TREATMENT OF PAIN, ANXIETY AND DEPRESSION. | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182875-A1 | N-(2-Hydroxyethyl)-N-Methyl-4-(Quinolin-8-yl(1-(Thiazol-4-ylmethyl)Piperidin-4-ylidene)Methyl)Benzamide | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2C8, UGT1A8 | OPRD1 445/4885OPRM1 120/4885OPRK1 417/4885 |
| US-20100160374-A1 | N-(2-Hydroxyethyl)-N-Methyl-4-(Quinolin-8-yl(1-(Thiazol-4-ylmethyl)Piperidin-4-ylidene)Methyl)Benzamide | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2C8, UGT1A8 | OPRD1 445/4885OPRM1 120/4885OPRK1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.